The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) is currently investigating six reported cases of capillary leak syndrome in people who were vaccinated with Spikevax, previously known as COVID-19 vaccine Moderna.
These six cases are out of over 61.6 million doses of the Moderna vaccine administered in the European Union and the European Economic Area (Norway, Iceland and Liechtenstein) and since it received authorization in January 2021. The EMA also pointed out that currently there is no evidence of a causal link between the Moderna vaccine and capillary leak syndrome.
Categories